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Abstract. Evaluation of an esterase annotated as 26D 
isolated from a marine metagenomic library is 
described. Esterase 26D was found to have a unique 
substrate scope, including synthetic transformations 
which could not be readily effected in a synthetically 
useful manner using commercially available enzymes. 
Esterase 26D was more selective towards substrates 
which had larger, more sterically demanding 
substituents (i.e. iso-propyl or tert-butyl groups) on the 
β-carbon, which is in contrast to previously tested 
commercially available enzymes which displayed a 
preference for substrates with sterically less demanding 
substituents (i.e. methyl group) at the β-carbon.  
Keywords: Esterase; Metagenomic Library; 
Stereochemistry; Biocatalyst; Enantiopurity 
Introduction 
Due to the importance of stereochemistry in drug 
discovery and the associated clinical and regulatory 
implications, the capability of producing 
enantiomerically pure synthons and Active 
Pharmaceutical Ingredients (APIs) in an efficient, 
highly stereoselective manner has never been more 
important.[1] Moreover, with increasing focus on 
“green” synthetic routes, a requirement exists for 
technologies which operate under milder conditions 
and minimise waste generation. Biocatalysis has 
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Biocatalysts are inherently stereoselective and many 
can outperform alternative methods prevalent in 
asymmetric synthesis, such as transition metal 
catalysis or chiral auxiliary chemistry.[3] In addition 
to the aforementioned advantages for enantioselective 
synthesis, biocatalysts are also obtained from 
renewable resources, can operate at neutral pH and 
wide ranges of temperatures, and are safe for both 
humans and the environment. Hence, there are 
significant advantages to this enabling technology 
when compared to “traditional” organic synthesis, 
which often relies on harsh reaction conditions or 
heavy metal catalysts.[2a, 4] 
Hydrolytic biocatalysts are very important to 
pharmaceutical, chemical and food industries.[5] 
These enzymes can be used to effect achiral 
transformations, however their primary use in 
synthetic chemistry is in asymmetric synthesis, where 
they can lead to enantioselective (dynamic) kinetic 
resolutions of esters and related compounds.[6] 
Esterases (EC 3.1.1.1) and lipases (EC 3.1.1.3) are 
sub-groups of hydrolases. Esterases and lipases 
catalyse the hydrolysis of short chain and long chain 
glycerol esters, respectively.[6a, 7] 
A common strategy employed for the discovery of 
novel biocatalysts is through functional metagenomic 
screening to discover proteins with novel 
sequences.[8]  
There exists a requirement for new enzyme 
discovery, not least from the point of view of 
investigation of new activities and functionality,[9] as 
well as from the perspective of novel substrate 
specificity. The dereplication of functionally active 
clones is a vital step in the identification of novel 
biocatalysts. The DNA sequencing of the novel 
biocatalysts can be searched against large sequence 
databases such as NCBI, which currently contains 
over 125 million sequences of different proteins. [10] 
This step of bioinformatic dereplication of positive 
clones at an early stage of the process, saves much 
time and cost on downstream analysis. Furthermore, 
these newly discovered biocatalysts can act as 
templates for further evolution, starting from a point 
at which the enzyme displays some activity for the 
target transformation. 
 
The marine environment is an unexploited resource 
for the mining of hydrolases such as esterases and 
lipases. [11] This niche environment harbours a wide 
range of enzymes that tolerate varying reaction 
conditions such as high salt concentration, high 
pressure and pH tolerance, as well as functioning in 
extreme temperatures, which enable their use in 
diverse applications including industrial scale 
transformation. [12] In the past when using traditional 
microbiology techniques, only a minority of the 
bacteria were culturable from a given environment 
and therefore a vast array of important enzymes could 
have been overlooked. [13] To combat this challenge, 
culture-independent techniques have now been 
successfully employed. The construction and 
functional screening of large metagenomic libraries 
have successfully uncovered many novel biocatalysts. 
[14] Furthermore the screening of these libraries can be 
adapted to high-throughput (103 to 105 variants/day) 
or ultrahigh-throughput (106 to 109 variants/day) 
functional screening assays. [15]  
Previously, our group [11] and others have had success 
with enzyme mining in niche environments as a 
biocatalyst source.[16] The marine environment, which 
has bestowed upon us many pharmaceutically 
interesting natural products, has proven to be a rich 
source of protein diversity.[11, 17]  
 
Exploring the potential of the novel biocatalysts in 
enantioselective synthesis 
 
Via the culture-independent sampling of the marine 
environment, a number of enzymes were identified in 
our laboratory as having hydrolytic activity through 
use of a tributyrin screen. The hydrolase family of 
enzymes  make up approximately 55% of all enzymes 
used in biocatalytic processes, with only 8% of these 
being esterases.[18] Following a screen of target 
substrates with these biocatalysts, esterase 26D was 
identified as an active and selective enzyme when 
tested, showing an altered substrate preference to 
previously tested commercial hydrolases.[1b, 19] 
Esterase 26D shows greater selectivity when the 
substituent on the β-carbon is a tert-butyl group 
(sterically bulky) versus a methyl group.  
Results and Discussion 
The novel esterase 26D was identified in a functional 
screen of an Axinella dissimilis marine sponge 
metagenomic library (n = 20,352 clones) constructed 
in E. coli EPI300 cells using the fosmid vector 
pCCFOS1.  Comparative analysis of the gene 
sequence encoding the 26D esterase revealed 
sequence identity (71%) with hydrolase 
WP_108845108.1 from a Phyllobacteriaceae 
bacterium and a hypothetical protein (70%) 
OUW21162.1 from a Rhizobiales bacterium. The 
clustering tree demonstrated that the 26D sequence 
branched on the same node as the aforementioned 
proteins, (WP_108845108.1 (■) and OUW21162.1 
(●)) however importantly the 26D esterase was on a 
distinct branching point to these (Figure 1). The 
percentage identity of the sequences in the tree, range 
from 44-71% compared to 26D. We theorized that 
this novel sequence could give rise to a novel 
functioning esterase with a unique substrate profile 
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Figure 1. Clustering Tree to define the uniqueness of the esterase positive clone 26D  
 
 




No. of enzymes which gave  
 >10% conversion 
No. of enzymes which furnished  
acid product in 90% ee 
1 Me 15 7 
2 Et 5 1[a] 
3 iPr 5 1 
4 tBu 2
[b] 1 
(a) Use of co-solvent required  (b) Heating to 40 C required 
 
Previous work in our group investigated the kinetic 
resolution of 3-arylalkanoic acids. Using a systematic 
approach with commercial enzymes and by varying 
the co-solvent, a range of compounds were resolved 
with excellent enantiopurity (Table 1).[1b, 19] One of 
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centre is not adjacent to the reacting site (i.e. at the α-
carbon) but at the β-carbon, which brings about 
significant challenges in terms of selectivity and 
activity.[1b, 19-20] 
Notably, from this previously completed screen the 
number of enzymes which processed the substrate 
decreased as the steric bulk of the β-substituent 
increased, Table 1.[19] Concurrently the number of 
enzymes exhibiting enantiodiscrimination also 
decreased. In particular, enzymatic hydrolysis of 
substrate 5 bearing a t-butyl substituent was 
extremely challenging, with only two of the 
previously screened commercial hydrolases showing 
activity. After considerable optimisation of the 
conditions for the biotransformation (immobilised 
Candida Antarctica Lipase B as the biocatalyst), the 
optimum outcome achieved led to the acid product in 
excellent enantiopurity (98% ee) with moderate 
conversion (23%) in 72 hours at 40 °C (Scheme 1). 
Even under the optimised conditions, the kinetic 
resolution of 5 is of limited synthetic utility as the 
enantiopurity of the recovered ester is, of necessity, 
compromised by the limited extent of reaction.[19] 
One possible explanation for this given by Müller et 
al is that, given the paucity of natural products 
featuring the t-butyl group, enzyme evolution in 
nature to accommodate this sterically demanding 
substituent is less likely.[21] 
 
 
Scheme 1: Previously screened hydrolysed-mediated kinetic resolution of (±)-ethyl 4,4-dimethyl-3-
phenylpentanoate (±)-5 at variable reaction times and temperature.[19] 
 
 
In this work identifying an enzyme which would 
hydrolyse substrate 5, the challenging substrate, in a 
synthetically useful manner would be very attractive. 
Accordingly, wild type esterase 26D was tested for 
activity against the challenging ester substrate 5. 
Gratifyingly, in the initial screens using whole cells 
expressing the wild type esterase 26D both activity 
and excellent enantioselectivity were seen with 
substrate 5. Whole cells expressing the esterase 
furnished the acid product in excellent enantiopurity 
(98% ee) with 21% conversion (Ecalc) (Table 2, entry 
5).   
In light of this result, screening this novel enzyme 
against the series of esters 1-4 was undertaken to 
probe the substrate scope of the enzyme by varying 
the alkyl substitution on the β-carbon (as summarised 
in Table 2). Interestingly, esterase 26D, while active 
across the series, displayed the opposite trend to all 
other enzymes screened against this similar series, 
with enantioselectivity increasing with increased 
steric demand at the β-substituent. Hydrolysis of the 
esters bearing ethyl (3) and isopropyl (4) substituents 
proceeded with good enantioselectivity, while 
decreased selectivity was seen with the smaller 
methyl substituent, even though resolution of this 
derivative was by far the most efficient in our earlier 
study.[1b, 19] 
Interestingly resolution of the trifluoromethyl 
substituted ester 2 was more efficient than that of the 
methyl derivative 1 under the same conditions. 
While the hydrolysis of ester 5 was promising (Table 
2, entry 5), to enhance its synthetic utility, process 
optimisation was undertaken (Table 2, entry 6) 
involving repeated additions of the biocatalyst at 0, 
12 and 24 hours, which led to recovery of the ester in 
73% ee albeit with a reduction in the enantiopurity of 
the acid (91% ee) under these more forcing 
conditions. This result demonstrates that with further 
optimisation, esterase 26D can lead to a synthetically 
feasible kinetic resolution, whereby both 
enantiomeric series can be accessed. Use of 
alternative co-solvents (1,4-dioxane, MTBE, EtOH), 
variation of pH (6 to 7.8) and extended reaction (72 
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Ecalc[b] [22] Ester Acid 
 
1 Me[c] 24 25 22 18 (S) 63 (R) 5  
2 CF3[c] 24 60 42 64 88   
3 Et[d] 24 30 24 31(S) 96 (R) 66  
4 iPr[c] 24 -[g] 42 65 (R) 88 (S) 31  
5 tBu[c] 24 30 21 26 (R) 98 (S) 127  
6 tBu[e] 48 -[g] 45 73 (R) 91(S) 40  
7 tBu[f] 48 -[g] 37 55 (R) 93 (S) 47  
 
(a) Conversion was estimated using 1H NMR spectroscopy by integration of the signal for esters and 
alcohols; (b) Conversion (Ecalc) and the enantiomeric ratio (E) were calculated from enantiomeric 
excess of substrate ester (ees) and product acid (eep); (c) 50 mg/mL of whole cells expressing esterase 
26D; (d) 25 mg/mL of whole cells expressing esterase 26D; (e) 50 mg/mL of whole cells expressing 
esterase 26D was added in three portions, 0h, 12 h and 24 h; (f) 150 mg/mL of whole cells expressing 
esterase 26D; (g) percentage conversion of ester to acid could not be determined by 1H NMR 
spectroscopy analysis. 
 
Having established that 26D could be used for a 
transformation which was not readily achieved with 
existing biocatalysts, its substrate scope was further 
investigated. We had previously examined a panel of 
hydrolase enzymes in the kinetic resolution of 2-
phenylalkanols.[23] Excellent enantiopurities were 
obtained for a number of alcohol products when 
CAL-B was used as the biocatalyst. In contrast, 
esterase 26D was a poor biocatalyst for the resolution 
of 2-phenylalkanols. A range of ester substrates was 
screened, with the substituent on the β-carbon (R1) as 
well as the substituent (R2) on the carboxylic acid 
moiety of the ester being varied (Table 3). Product ee 
was poor to moderate, although in some instances 
hydrolysis was seen for substrates (14 and 15) which 
were not processed by CAL-B [23] (Table 3, entries 4 
and 5), further highlighting the different profile in 
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Table 3. Kinetic resolution of 2-phenylalkanols using esterase 26D 
 
Entry Compound R1 R2 
Conversion (%) % ee 
E[22] 
1H NMR [a] Ecalc[b] [22] Ester Alcohol 
1 11 Me Ph 81 67 36 (R) 18 (S) 2 
2 12 Me tBu 56 15 3 (R) 19 (S) 2 
3 13 Et Ph 55 48 37 40 3 
4 14 Et tBu 55 34 40 77 11 
5 15 iPr iPr 55 49 29 30 2 
6 16 iPr
 
Ph 25 19 14 61 5 
7 17 iPr tBu -[c] 15 16 91 25 
8 18 Me Bn 22 21 10 38 2 
 
(a) Conversion was estimated using 1H NMR spectroscopy by integration of the signal for esters and 
alcohols; (b) conversion (Ecalc) and enantiomeric ratio (E) were calculated from enantiomeric excess of 
substrate ester (ees) and alcohol product (eep); (c) percentage conversion of ester to alcohol could not be 
determined by 1H NMR spectroscopy analysis   
 
 
We then turned our attention to applying the atypical 
substrate acceptance of esterase 26D to a 
pharmaceutical intermediate, since assimilation of a 
novel biocatalyst into an industrially relevant 
synthetic route would underline its value.  
This work was initially extended to cyclic substrates 
27-29, as summarised in Table 4. Esterase 26D 
hydrolyses acetates of α- and β-tetralols (27 & 28) 
and 1-indanol (29), affording high conversion to the 
alcohols 31 & 32 but with very poor 
enantiodiscrimination. 
Following on from this work, the novel acetates 25 
and 26 were prepared by acetylation of the 
corresponding tetralols 23 and 24, which were 
accessed by reduction of the tetralone 22 (Scheme 2). 
An intermediate in the synthesis of the Pfizer 
antidepressant sertraline, racemic tetralone 22 was 
obtained from the condensation of 1-napthol and 1,2-
dichlorobenzene in the presence of a strong Lewis 
acid. Enantiopure (4S)-tetralone 22 was also reduced 
and acetylated. The tetralin core (α- or β- substituted) 
is in itself a privileged moiety in drug discovery, 






Scheme 2. Synthesis of acetates 25 and 26 
 
When the trans- and cis- acetates 25 and 26 were 
exposed to esterase 26D, hydrolysis of the trans-
acetate 25 is more rapid than that of the cis-acetate 26 
(Table 4 entry 4 and 5). Excellent enantioselectivity 
was observed in the formation of the cis-tetralol 24 
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as a synthetic intermediate for sertraline,[25] this 
observation is particularly interesting and highlights 
the potential of the novel biocatalyst to be utilised for 
the resolution of pharmaceutically related 
compounds. Absolute stereochemistries of the 
biotransformation products were deduced by 
comparing the HPLC traces with that of the (4S)-
tetralol and the corresponding acetates. 
 






Conversion % ee 
E[22] 
1H NMR Ecalc[a] [22] Ester Alcohol 
1 27 4 -[b] 5 30 10 2 
2 28 1 -[b] 86 32 5 1 
3 29 2 22 50 4 4 1 
4 25 24 38 36 ~31[c] 55 (1R,4S) 5 
5 26 24 20 18 21 93 (1R,4R) 39 
(a) Conversion (Ecalc) and the enantiomeric ratio (E) were calculated from enantiomeric excess of 
substrate ester (ees) and product alcohol (eep); (b) percentage conversion of ester to alcohol could not be 




In conclusion, the novel esterase 26D acts as a 
synthetically valuable biocatalyst displaying a unique 
substrate scope, at least within the range of 
biocatalysts which we have explored, and to date is 
the optimum biocatalyst for the resolution of the 
challenging ester substrate 5, highlighting the 
importance of metagenomic screening as a valuable 
approach for the discovery of novel biocatalysts. The 
success in resolving an ester substrate where the 
chirality lies in the acid portion (6-10) relative to the 
other substrates explored where the chirality lies in 
the alcohol (e.g. compounds 11-18 and 25-29) moiety 
is unsurprising in an esterase.[26] Furthermore, a 
potential intermediate in the synthesis of sertraline 
(compound 26) was resolved in excellent 
enantiopurity, suggesting the potential of this 




Solvents were distilled prior to use as follows: 
dichloromethane was distilled from phosphorus 
pentoxide, ethyl acetate was distilled from potassium 
carbonate. Hexane was distilled prior to use. Organic 
phases were dried over anhydrous magnesium sulfate. 
Infrared spectra were recorded neat using a Perkin 
Elmer FTIR UATR2 spectrometer.1H (300 MHz) and 
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Bruker Avance 300 MHz NMR spectrometer and all 
spectra were recorded at room temperature (̴ 20 °C) in 
deuterated chloroform (CDCl3), unless otherwise 
stated, using tetramethylsilane (TMS) as an internal 
standard and chemical shifts (δH and δC) are reported 
in parts per million (ppm) and coupling constants are 
expressed in Hertz (Hz). Low resolution mass spectra 
were recorded on a Waters Quattro Micro triple 
quadrupole spectrometer in electrospray ionisation 
(ESI) mode using 50% water/acetonitrile containing 
0.1% formic acid as eluent. High resolution mass 
spectra (HRMS) were recorded on a Waters LCT 
Premier Time of Flight spectrometer in electrospray 
ionisation mode (ESI) using 50% water/acetonitrile 
containing 0.1% formic acid as eluent. Wet flash 
chromatography was performed using Kieselgel 
Silica Gel 60, 0.040–0.063 mm (Merck). Thin layer 
chromatography (TLC) was carried out on precoated 
silica gel plates (Merck 60 PF254). Visualisation was 
achieved by UV (254 nm) light detection and KMnO4 
staining. Candida Antarctica lipase B (immobilised 
on ImmoBead 150) was purchased from Sigma-
Aldrich chemical company. All enzymatic reactions 
were performed on a VWR Incubating Mini Shaker 
4450. All reagents are analytical grade and purchased 
from Sigma-Aldrich, Acros Organics, Fluka or TCI. 
Enantiomeric excess values were measured by high 
performance liquid chromatography (HPLC) using a 
Chiralcel® OB-H column  (5 × 250 mm), Chiralcel® 
OD-H column (5 × 250 mm), Chiralcel® OJ-H 
column (5 × 250 mm) and Chiralpak® IB (5 × 250 
mm) purchased from Daicel Chemical Industries, 
Japan. Phenomenex Amylose 1 column (5 × 250 
mm), Phenomenex Amylose 2 column (5 × 250 mm), 
Phenomenex Cellulose 4 column (5 × 250 mm), 
purchased from Phenomenex Inc., UK. Mobile phase 
and flow rate are included where appropriate, and the 
detector wavelength was 209.5 nm. HPLC analysis 
was performed on a Waters alliance 2690 separations 
module with a PDA detector.  
 
Expression and purification of lipase/esterase  
His-tagged esterase 26D fusion proteins derived from 
a tributyrin screen of a pCC1FOS™ (Epicentre) 
metagenomic library transformed in EPI300™ 
Electrocompetent E. coli were prepared for 
recombinant protein expression. Single colonies were 
inoculated in LB (Luria-Bertani) medium 
supplemented with kanamycin (50 μg/ml), 
chloramphenicol (50 μg/ml) and streptomycin (75 
μg/ml) and incubated at 37°C with shaking at 180 
rpm overnight. Overnight cultures were transferred 
(1%) to fresh media with antibiotics and grown to an 
OD600nm of 0.8-1.0, at which point the medium was 
supplemented with 0.5 mM IPTG (Melford) to induce 
recombinant protein expression. After 4 hrs post-
induction, the culture was centrifuged at 12,000 rpm 
for 10 min at 4°C to harvest the cells. The cell pellet 
was stored at -80°C until ready for expression 
analysis. 
Bioinformatic Dereplication for Novel Activity 
The DNA sequences of the positive clone was 
bioinformatically aligned using Clustal Omega [27] 
and a consensus sequence was defined using Jalview 
Version 2 [28]. A Translated BLAST: blastx search 
was conducted against the NCBI Non-redundant 
protein sequence database [29]. The cluster 
relationship of 26D was inferred using the Neighbor-
Joining method. The distances were computed using 
the Poisson correction method and are in the units of 
the number of amino acid substitutions per site. The 
analysis involved 100 amino acid sequences of the 
top BLAST hits by sequence identity. All ambiguous 
positions were removed for each sequence pair. This 
analysis was conducted in MEGA X. 
 
Lipase-catalysed hydrolysis reactions 
In a typical experiment, 50 mg of whole cells 
expressing esterase 26D were added to a 15 mL 
centrifuge tube (unless otherwise stated) followed by 
0.1 M potassium phosphate buffer at pH 7.2 (900 
µL/1000 µL). Substrates 1 - 5, 11 - 18 and 25 - 29 (20 
mM) were dissolved in 100 µL DMSO (10% v/v) and 
then added to the centrifuge tube to make the total 
volume 1 mL. The reaction mixture was agitated at 
400-450 rpm and incubated at 30 °C for 24 h unless 
otherwise stated. Ethyl acetate (3mL) was added to 
the centrifuge tube and the reaction mixture was 
centrifuged at 5000 rpm for 10 minutes. The layers 
were separated, the aqueous layer was washed with 
ethyl acetate (2 × 3 mL), the combined organic 
extracts were filtered through Celite® and 
concentrated under reduced pressure. The entire 
reaction sample was analysed by 1H NMR 
spectroscopy, reconcentrated and dissolved in a 
mixture of iPrOH /hexane [10:90 (HPLC grade)] and 
enantiopurity determined by chiral HPLC analysis.  
 
Compounds 1, 3-5, 7-12, 15, 18, 21, 23-24 and 27-29 
were synthesised according to previously reported 
methods.[19, 23, 25, 30]  Details of novel compounds are 
given in the SI.  
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